Organization | European Lung Cancer Working Party

European Lung Cancer Working Party Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Brussels Belgium (1989)

Organization Overview

First Clinical Trial

2000

NCT00658580

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2009

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (6)

cisplatin (platinol) (4 trials)

docetaxel (taxotere) (2 trials)

epirubicin (ellence) (1 trial)

etoposide (vepesid) (1 trial)

gemcitabine (gemzar) (1 trial)

ifosfamide (ifex) (2 trials)

Drugs in Phase 2 Trials (4)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (2 trials)

valproic acid (depakene) (2 trials)

vindesine (Eldisine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Lung Neoplasms (Phase 3)

Mesothelioma (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 10